- ISSN 1672-5069
- CN 34-1270/R
- CODEN SGZHBF
Journal of Practical Hepatology ›› 2026, Vol. 29 ›› Issue (3): 324-327.doi: 10.3969/j.issn.1672-5069.2026.03.002
Previous Articles Next Articles
Tang Weiguo, Liu Yuan
Received:2024-05-23
Online:2026-05-10
Published:2026-05-18
Tang Weiguo, Liu Yuan. Yttrium-90 microsphere radioembolization in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2026, 29(3): 324-327.
| [1] Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.Eur J Nucl Med Mol Imaging, 2022, 49(5): 1682-1699. [2] Vogel A,Martinelli E,Vogel A,et al.Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMOclinical practice guidelines. Ann Oncol, 2021, 32(6): 801-805. [3] 王斯妮, 贾中芝, 胡红杰, 等. 钇-90微球的特性、放射栓塞的操作技术及安全防护——钇-90微球放射栓塞系列回顾(一). 介入放射学杂志, 2017, 26(10): 952-958. [4] Biederman DM,Titano JJ,Tabori NE, et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: Resin versus glass microspheres. J Vasc Interv Radiol, 2016, 27(6): 812-821,e2. [5] Bester L,Meteling B,Pocock N,et al.Radioembolization versus standard care of hepatic metastases:Comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol, 2012, 23(1): 96-105. [6] Sangro B, Martínez-Urbistondo D, Bester L, et al. Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Hepatology, 2017, 66(3): 969-982. [7] 郑丽丽, 贾中芝, 王斯妮, 等. 钇-90微球放射栓塞治疗肝脏恶性肿瘤的不良反应和并发症——钇-90微球放射栓塞系列回顾(五). 介入放射学杂志, 2018, 27(2): 190-196. [8] Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: Background,quality improvement guidelines, and future directions. J Vasc Interv Radiol, 2017, 28(1): 1-15. [9] Müller SP, Ezziddin S, Antoch G, et al. Selektive intraarterielle radiotherapie (SIRT) malignerlebertumoren. Nuklearmedizin, 2017, 56(5): 162-170. [10] Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol, 2008, 31(5): 431-438. [11] Hamm CA, Busch F, Pöhlmann A, et al. Non-invasive imaging biomarkers to predict the hepatopulmonary shunt fraction before transarterial radioembolization in patients with hepatocellular carcinoma. J Hepatocell Carcinoma, 2023, 10: 27-42. [12] Ward TJ, Tamrazi A, Lam MG, et al. Management of high hepatopulmonary shunting in patients undergoing hepatic radioembolization. J Vasc Interv Radiol, 2015, 26(12): 1751-1760. [13] Schiro BJ, Amour ES, Harnain C, et al. Management of high hepatopulmonary shunts in the setting of Y90 radioembolization. Tech Vasc Interv Radiol, 2019, 22(2): 58-62. [14] Theysohn JM, Schlaak JF, Müller S, et al. Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol, 2012, 23(7): 949-952. [15] Thüring J, Zimmermann M, Bruners P, et al. Short-term oral sorafenib for therapy of intratumoral shunts of hepatocellular carcinoma to enable intraarterial treatment. Cardiovasc Intervent Radiol, 2019, 42(10): 1494-1499. [16] Bledsoe TJ, Nath SK, Decker RH. Radiation pneumonitis. Clin Chest Med, 2017, 38(2): 201-208. [17] Collins J, Salem R. Hepatic radioembolization complicated by gastrointestinal ulceration. Semin Intervent Radiol, 2011, 28(2): 240-245. [18] Carretero C, Munoz-Navas M, Betes M, et al. Gastroduodenal injury after radioembolization of hepatic tumors. Am J Gastroenterol, 2007, 102(6): 1216-1220. [19] Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma acrossbarcelona clinic liver cancer stages: a European evaluation. Hepatology, 2011, 54(3): 868-878. [20] Lam MGEH, Banerjee S, Louie JD, et al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc Intervent Radiol, 2013, 36(6): 1536-1547. [21] Hamami ME, Poeppel TD, Müller S, et al. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med, 2009, 50(5): 688-692. [22] Kallini JR, Gabr A, Thorlund K, et al. Comparison of the adverse event profile of TheraSphere© with SIR-spheres© for the treatment of unresectable hepatocellular carcinoma: A systematic review. Cardiovasc Intervent Radiol, 2017, 40(7): 1033-1043. [23] Sun B, Lapetino SR, Diffalha SA, et al. Microvascular injury in persistent gastric ulcers after yttrium-90 microsphere radioembolization for liver malignancies. Hum Pathol, 2016, 50: 11-14. [24] Feely M, Tondon R, Gubbiotti M, et al. Gastrointestinal tract injury by yttrium-90 appears largely restricted to resin microspheres but can occur years after embolization. Am J Surg Pathol, 2022, 46(9): 1234-1240. [25] Braat MN, van Erpecum KJ, Zonnenberg BA, et al. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol, 2017, 29(2): 144-152. [26] Maleux G, Albrecht T, Arnold D, et al. Predictive factors for adverse event outcomes after transarterial radioembolization with yttrium-90 resin microspheres in Europe: Results from the prospective observational CIRT study. Cardiovasc Intervent Radiol, 2023, 46(7): 852-867. [27] Prince DS, Schlaphoff G, Davison SA, et al. Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study. J Gastroenterol Hepatol, 2022, 37(11): 2173-2181. [28] Piana PM, Gonsalves CF, Sato T, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol, 2011, 22(10): 1373-1379. [29] Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology, 2013, 57(3): 1078-1087. [30] Kessler J, Park JJ. Yttrium-90 radioembolization after local hepatic therapy: How prior treatments impact patient selection, dosing, and toxicity. Tech Vasc Interv Radiol, 2019, 22(2): 112-116. [31] Seidensticker M, Seidensticker R, Damm R, et al. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One, 2014, 9(11): e112731. [32] Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med, 2000, 108(6): 481-486. [33] Parakh S, Gananadha S, Allen R, et al. Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: Clinical and pathologic findings. Asian J Surg, 2016, 39(3): 144-148. [34] Padia SA, Johnson GE, Lewandowski RJ, et al. Transarterial yttrium-90 radioembolization of hepatocellular carcinoma perfused by the cystic artery: Multi-institutional feasibility study. J Vasc Interv Radiol, 2020, 31(12): 2022-2027. [35] Powerski M, Busse A, Seidensticker M, et al. Prophylactic embolization of the cystic artery prior to radioembolization of liver malignancies--an evaluation of necessity. Cardiovasc Intervent Radiol, 2015, 38(3): 678-684. [36] Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol, 2008, 19(5): 691-697. [37] Devulapalli KK, Fidelman N, Soulen MC, et al. 90Y radioembolization for hepatic malignancy in patients with previous biliary intervention: Multicenter analysis of hepatobiliary infections. Radiology, 2018, 288(3): 774-781. [38] Parikh RS, Abousoud O, Hunt S, et al. Infection rates following hepatic embolotherapy in patients with prior biliary interventions: Comparison of single-drug moxifloxacin and multidrug antibiotic prophylaxis. J Vasc Interv Radiol, 2021, 32(5): 739-744. [39] Mascarenhas N, Ryu RK, Salem R. Erratum: hepatic radioembolization complicated by abscess. Semin Intervent Radiol, 2017, 34(03): 303-304. [40] Hoffmann RT, Jakobs TF, Kubisch CH, et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? Eur J Radiol, 2010, 74(1): 199-205. [41] Leong QM, Lai HK, Lo RG, et al. Radiation dermatitis following radioembolization for hepatocellular carcinoma: a case for prophylactic embolization of a patent falciform artery. JVasc Interv Radiol, 2009, 20(6): 833-836. [42] Su YK, Mackey RV, Riaz A, et al. Long-term hepatotoxicity of yttrium-90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver. J Vasc Interv Radiol, 2017, 28(11): 1520-1526. [43] Wang DS, Louie JD, Kothary N, et al. Prophylactic topically applied ice to prevent cutaneous complications of nontarget chemoembolization and radioembolization. J Vasc Interv Radiol, 2013, 24(4): 596-600. [44] Li X, Montazeri SA, Paz-Fumagalli R, et al. Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres. Eur J Nucl Med Mol Imaging, 2021, 48(8): 2624-2634. [45] Alexander ES, Pantel AR, Carlin SD, et al. Prospective study of systemic yttrium-90 elution during radioembolization of hepatic metastases. J Vasc Interv Radiol, 2020, 31(12): 2007-2013.e1. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
